NCT05264051 MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
| NCT ID | NCT05264051 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Liver Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2022-04-18 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2022-04-18 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.
Eligibility Criteria
Inclusion Criteria: * Patients who are already scheduled for an MRI for routine clinical purposes will be evaluated Exclusion Criteria: * \<18 yrs. of age
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05264051 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05264051 currently recruiting?
Yes, NCT05264051 is actively recruiting participants. Contact the research team at Omar.Jamil@uchospitals.edu for enrollment information.
Where is the NCT05264051 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT05264051 clinical trial?
NCT05264051 is sponsored by University of Chicago. The trial plans to enroll 1,200 participants.